
REUTERS.COM
cancer
Pfizer signs licensing deal worth about $6 billion with China's 3SBio for cancer drug
SUMMARY
Pfizer has signed a $6 billion licensing agreement with 3SBio Inc to develop a drug aimed at treating certain cancers. The drug candidate is being tested for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors in China.
3SBio plans to start a Phase III trial this year, and the drug has received FDA clearance for its Investigational New Drug application.
The agreement grants Pfizer a global license, excluding China, for the drug SSGJ-707, with a potential option for commercialization rights in China.
Pfizer will manufacture the drug in North Carolina and Kansas and plans a $100 million equity investment in 3SBio.
-->
Click below to share
Read next
▶︎ Click here for more breaking news
-->
Recommended for you
Trending now
-->